The European Medicines Agency has granted orphan drug status to LTI-03, an inhaled therapy being developed for people with ...

Columnist Kylene Henderson is starting the year by focusing on progress and wellness, even if it means only small changes.

New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Artificial intelligence has come a long way, writes columnist Sam Kirton, who argues for its role in medicine and in his own care with PF.

Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...

Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...